Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA). (18th August 2018)

• Record Type: Journal Article
• Authors: Miyazawa, Kazuo; Pastori, Daniele; Hammerstingl, Christoph; Cappato, Riccardo; Meng, Isabelle Ling; Kramer, Frank; Cohen, Ariel; Schulz, Anke; Eickels, Martin van; Lip, Gregory Y. H.; Marin, Francisco
• Is Part Of: Annals of medicine. Volume 50:Number 6(2018)
• Page Start: 511
• Page End: 518
• Publication Date: 2018-08-18
• Subjects: Atrial fibrillation -- non-vitamin K antagonist oral anticoagulant -- thrombus resolution -- biomarker; Medicine -- Periodicals; 610
• DOI: 10.1080/07853890.2018.1495337
• Languages: English
• ISSNs: 0785-3890

Abstract

Abstract: Background: Non-vitamin K antagonist oral anticoagulants including rivaroxaban are widely used for stroke prevention in patients with atrial fibrillation (AF). We investigated the relationship between plasma biomarkers (indicative of thrombogenesis, fibrinolysis and inflammation) and left atrial thrombus resolution after rivaroxaban treatment. Methods: This was an ancillary analysis of the X-TRA study, which was a prospective interventional study evaluating the use of rivaroxaban for left atrial/left atrial appendage (LA/LAA) thrombus resolution in AF patients. We assessed various biomarkers of thrombogenesis/fibrinolysis [D-dimer, plasminogen activator inhibitor-1 (PAI-1), prothrombin fragment 1 + 2 (F1, 2), thrombin–antithrombin (TAT) complexes, von Willebrand factor (vWF)] and inflammation [high-sensitivity interleukin-6 (hsIL-6), and high-sensitivity C-reactive protein (hsCRP)], measured at baseline and after 6 weeks' of rivaroxaban treatment. Results: There was a significant decrease in the mean levels of hsCRP, D-dimer, vWF, and TAT from baseline to end of treatment with rivaroxaban. Although none of the thrombogenesis/fibrinolysis biomarkers showed a significant relationship with thrombus resolution, high inflammatory biomarkers at baseline were significantly associated with an increased chance of the thrombus being completely resolved (hsIL-6) or reduced/resolved (hsCRP). Conclusions: Biomarkers of inflammation are significantly associated with LA/LAA thrombus outcomes in AF patients prospectively treated with rivaroxaban. KEY MESSAGES: Changes in the thrombogenesis/fibrinolysis biomarker levels reflected the expected pharmacodynamics of rivaroxaban. Higher levels of inflammation biomarkers were significantly associated with thrombus being completely resolved or reduced.